Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. Annual Sales of Farxiga reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Full Year and Q4 2024 results Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market. Dapagliflozin Drug Summary Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. AstraZeneca will make an upfront payment to Dizal of $600m and additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances. Explore the FARXIGA Market trends, size, and future outlook with DelveInsight's latest report. Gain insights into Companies, emerging therapies, and forecasts Much of the attention on AstraZeneca PLC in the past couple of years has focused on its blooming oncology franchise but its top earner is the pipeline-in-a-product Farxiga and sales of the SGLT2 inhibitor, which is approved type 2 diabetes, heart failure and chronic kidney disease, have soared again in the second quarter. Contact AstraZeneca for FARXIGA support savings card details, FAQs and patient assistance for eligible insured patients today. Invokana (canagliflozin, Janssen) Steglatro (ertugliflozin, Merck) FARXIGA's differentiation stems from its approval in multiple indications, notably HFrEF and CKD, beyond T2DM. Revenue Performance and Sales Trends AstraZeneca reported global sales of USD 4.3 billion for FARXIGA in 2022, a 25% increase from 2021 [4]. CEO Pascal Soriot remarked that "2022 has started strongly for AstraZeneca," adding "Farxiga achieved $1 billion revenue in the quarter and our oncology medicines delivered product sales growth of 18% [on a constant exchange rate basis], despite COVID-19 continuing to impact cancer diagnosis and … Farxiga's landmark first-quarter showing comes in contrast to a disappointment from AZ's leading oncology portfolio, which represents about a third of the company's sales. Farxiga, AstraZeneca's dapagliflozin product, is one of the largest global SGLT2 inhibitors and a core growth asset across type 2 diabetes, heart failure and chronic kidney disease. Global sales reached approximately $5.8 billion in 2023 and were on track for roughly $7 billion in 2024 based on AstraZeneca's reported quarterly performance. Learn more about savings and insurance support for FARXIGA® (dapagliflozin). Register today to receive a savings card. Compare prices and print coupons for Farxiga at major pharmacies. Find savings tips to help lower your prescription costs. Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%. Crestor sales were up 5% to $261 million. Respiratory & Immunology (R&I) sales in the quarter were up 27% to $2.1 billion. Symbicort sales were $684 million, up 31%. Fasenra sales were up 12% to $471 million. Breztri sales were up 29% … Annual Sales of Dapagliflozin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Compare Farxiga prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. In the decade since AstraZeneca's Farxiga first nabbed FDA approval to treat adults with type 2 diabetes, the drug has well surpassed blockbuster status, racking up additional indications and generating nearly $6 billion in sales in 2023. And it hasn't reached its peak yet, according to a … Dapagliflozin Generic Farxiga Drug Info Side Effects Dosage Medicare Scan to get these savings in the GoodRx app. Check your prescription Pricing is calculated based on your prescription details. FARXIGA® (dapagliflozin), a medication for people with chronic kidney disease (CKD), heart failure, and type 2 diabetes. The comprehensive new report detailing FARXIGA's impact and projected growth in the myocardial infarction treatment landscape over the next decade is now available, offering crucial insights into … AstraZeneca's best-selling asset in 2023 was Farxiga (dapagliflozin), indicated for chronic kidney disease, heart failure and type 2 diabetes. It brought in $5.96 billion, a 39% increase from the year before at constant exchange rates. DelveInsight's FARXIGA Market report covers size, trends, competitive landscape, and future outlook. Stay updated on the latest developments and forecasts. A generic version of Farxiga is available. Learn the differences in cost and dosages, and how to switch to generic Farxiga. In the second quarter, Farxiga hit $377 million in sales compared with $232 million for Jardiance and $177 million for Invokana. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. FY and Q4 2023 results Strong growth and pipeline momentum with three new medicines approved since the third quarter Farxiga and Jardiance pose affordability issues, says Maryland drug board The state's independent body approved resolutions stating that both drugs present affordability challenges. AstraZeneca has generated over $20.9 billion in sales revenue from Farxiga since its launch in 2014. Revenues obtained by AstraZeneca through Farxiga sales are nearly 30 times the median cost for research and development of a new drug estimated by experts. Get your Farxiga 5 mg Tablets, 30 Count Bottle from HealthWarehouse, your trusted online pharmacy. We offer affordable healthcare products that get delivered right to your door. Additional investment in new medicines continued to fuel our rapidly growing oncology and biopharmaceuticals therapy areas. Tagrisso's future was enhanced with its first regulatory approval in early, potentially-curable lung cancer and further national reimbursement in China in advanced disease. Farxiga again expanded its potential beyond diabetes, while tezepelumab promised real hope for … AstraZeneca has become the latest pharma group to set up a direct-to-consumer sales channel in the US, covering Farxiga, Airsupra, and FluMist. Find answers to common FAQs about FARXIGA tablet delivery and self-pay options with AstraZeneca Direct. FDA approvals for generic dapagliflozin mark the first potential US entries following Farxiga's patent expiry, intensifying competition in a multi-billion-dollar market already reshaped by Medicare price negotiation and AstraZeneca's authorized generic strategy. COVID-19 mAbs: licence fees Farxiga: sales milestones tralokinumab: sales milestones Lynparza: regulatory milestones Beyfortus: regulatory milestones Other Collaboration Revenue The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. AstraZeneca's strong sales, rising margins, and drug approvals drive impressive growth in 2025. Pay $0* a month for Brand-Name FARXIGA DOWNLOAD SAVINGS CARD Subject to eligibility and monthly savings limit. Restrictions apply. *Eligible commercially insured patients can get Brand-Name FARXIGA for as low as $0 as long as their doctor prescribes it. Not available for government-insured patients.